$CMRX News
Last published 1w ago
- 1w agoCMRXJazz Pharmaceuticals 2026 Third Quarter Earnings - CHIMERIX INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to Jazz Pharmaceuticals' 2026 third quarter earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will b
- 1mo agoCMRXJazz Pharmaceuticals - 1774277 - CHIMERIX INCEarnings Call TranscriptsSo really pleased with that. And on the heels of it, remember, we had stat-sig overall survival benefit for the triplet arm at the time of the first interim analysis with two additional scheduled OS analyses. And at that
- 1mo agoCMRXJazz Pharmaceuticals - 1774277 - CHIMERIX INCEarnings Call TranscriptsSo really pleased with that. And on the heels of it, remember, we had stat-sig overall survival benefit for the triplet arm at the time of the first interim analysis with two additional scheduled OS analyses. And at that
- 1mo agoCMRXJazz Pharmaceuticals - 1773771 - CHIMERIX INCEarnings Call TranscriptsGood afternoon, everyone. I'm Sean Larmond, Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley. Welcome to the Morgan Stanley Global Healthcare Conference. Before we commence, I need to make you aware of c
- 2mo agoCMRXWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - CHIMERIX INCEarnings Call TranscriptsThank you for joining us. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo, and I'm joined by Team Jazz today. Music, please. So I'm joined by Sam Pearce. She's the EVP and chief co
- 2mo agoCMRXWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - CHIMERIX INCEarnings Call TranscriptsThank you for joining us. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo, and I'm joined by Team Jazz today. Music, please. So I'm joined by Sam Pearce. She's the EVP and chief co
- 2mo agoCMRXZiihera GEA Investor Webcast - CHIMERIX INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Zahar G.E.A. Investor Webcast Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question an
- 1y agoCMRXLTRNPARIS:ALTMELantern Pharma Announces Appointment of Dr. Lee Schalop to Board of DirectorsBusiness WireSeasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage
- 1y agoCMRXChimerix Reports Fourth Quarter and Year End 2024 Financial ResultsGlobeNewswireNew Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by
- 1y agoBRDGCMRXWBASYTAKuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. The investigation ...
- 1y agoCMRXChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee
- 1y agoCMRXJAZZJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioGlobeNewswire-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash
- 1y agoJAZZCMRXJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have...
- 1y agoCMRXChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new
- 1y agoCMRXChimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse GliomaGlobeNewswirePotential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma PDUFA Target Action Date of August 18, 2025 No Advisory Committee Meeting Currently Planned to Discuss Application DURHAM, N.C., Feb.
- 1y agoCMRXChimerix to Present at JonesTrading Virtual Precision Medicine SymposiumGlobeNewswireDURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 1y agoCMRXChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to six new
- 1y agoCMRXChimerix to Speak Today at The White House Cancer Moonshot ForumGlobeNewswireDURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 1y agoCMRXChimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaGlobeNewswireDURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 1y agoCMRXChimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndGlobeNewswirePotential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10
- 1y agoCMRXChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new
- 2y agoCMRXChimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingGlobeNewswireDURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix, Inc. (CMRX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCMRXChimerix Reports Third Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment
- 2y agoCMRXChimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024GlobeNewswireDURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new
- 2y agoCMRXChimerix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireDURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee
- 2y agoCMRXChimerix, Inc. (CMRX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCMRXChimerix Reports Second Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date
- 2y agoCMRXNNVCSIGAVERURapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs MarketGlobeNewswirePALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral diseases. Customers are
- 2y agoCMRXChimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024GlobeNewswireDURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees
- 2y agoCMRXChimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceGlobeNewswireDURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix, Inc. (CMRX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCMRXChimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date,
- 2y agoCMRXChimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024GlobeNewswireDURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to four new
- 2y agoCMRXUFPTChimerix Appoints Marc D. Kozin to Board of DirectorsGlobeNewswireDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateGlobeNewswire– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and
- 2y agoCMRXChimerix to Present at TD Cowen 44th Annual Health Care ConferenceGlobeNewswireDURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024GlobeNewswireDURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Appoints Lisa Decker to Board of DirectorsGlobeNewswireDURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Promotes Michelle LaSpaluto to Chief Financial OfficerGlobeNewswireDURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 2y agoCMRXChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new
- 2y agoCMRXChimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial OfficerGlobeNewswireDURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 3y agoCMRXChimerix, Inc. (CMRX) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoCMRXChimerix Reports Third Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewswire– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to
- 3y agoCMRXChimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023GlobeNewswireDURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
- 3y agoCMRXChimerix to Participate in Upcoming Investor ConferencesGlobeNewswireDURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly